Consider a treatment option | Rubraca® (rucaparib) tablets
For women with recurrent ovarian cancer,
Consider a treatment option
you take at home.

With the recent developments regarding COVID-19, Clovis Oncology understands that you are minimizing your time away from home. That's why we're committed to supporting you and your healthcare team. Maintenance therapy with a PARP inhibitor is a treatment option you can use at home.

Don’t be afraid to ask questions. Your healthcare team can help you more if you speak up about your concerns and stay in regular contact.

Rubraca may be right for you, right now

Woman image
Rubraca maintenance
If chemotherapy helped shrink your cancer, Rubraca maintenance may help keep cancer from growing or returning for a longer period of time.
Your doctor tells you you’re having a response to chemotherapy, which means your cancer has stopped growing or is shrinking
After 2 image
After 2 image

Rubraca can help control recurrent ovarian cancer

Rubraca helps extend your response to chemotherapy
In the maintenance clinical trial, women were switched to Rubraca or placebo after they responded to chemotherapy.
Rubraca provided more time without disease progression in women who were BRCA+ or had HRD
Chart image
Chart image
BRCA stands for Breast Cancer susceptibility gene.
HRD stands for Homologous Recombination Deficiency.
The Rubraca maintenance trial also looked at 141 women who experienced partial response to chemotherapy
  • 26 of the women who didn’t fully respond to chemotherapy still had their tumor(s) shrink or disappear with Rubraca
  • 10 women had a complete response (their scans showed no signs of cancer)
  • 16 women had a partial response (their scans showed that the tumor with the largest diameter decreased in size by at least 30%)
What does response mean?
When a tumor shrinks because of treatment, this is called response. Complete response means that all tumors disappeared during the course of treatment. Partial response is defined by the tumor with the largest diameter decreasing in size by at least 30%.
Rubraca should be taken twice daily, with or without food
Your oncologist will tell you how much Rubraca you should take. Most women start by taking 600 mg of Rubraca twice a day (total of 1200 mg/day). This means taking a total of four 300 mg tablets/day.
Pills graphic
Pills graphic
Rubraca should be stored at room temperature, between 68°F and 77°F (20°C to 25°C).
Dose adjustments
  • Your oncologist may lower your dose or tell you to stop taking Rubraca for a time; this is a way to help manage side effects
  • In the clinical trial, about half of the women taking Rubraca had their dose lowered—they still experienced a delay in disease progression
Important Dosing Rules
Do not change your dose or stop taking Rubraca unless your oncologist tells you to
Do not take an extra dose to make up for a missed dose. If you miss a dose, just take your next dose at your regularly scheduled time
If you vomit after taking a dose, do not take an extra dose. Take your next dose at your regularly scheduled time
If you take too much Rubraca, call your oncologist or go to the nearest emergency room right away
Three Cards

Discover how Rubraca may help maintain the response to platinum-based chemotherapy

maintenhance Learn more

How to take Rubraca

Pill Learn more

Find out about the possible side effects of Rubraca

side effects Learn more

Click here if you have advanced ovarian cancer with a BRCA mutation and have finished at least 2 chemotherapy medicines.  arrow

Please note: you can rollover any word that is gold and in italics to view the definition.

INDICATIONS

What is Rubraca?

Rubraca® (rucaparib) tablets are a prescription medicine used for:

  • The maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
  • The treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children. 

SELECT IMPORTANT SAFETY INFORMATION

Read full

warning Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

warning Symptoms of low blood cell counts are common during treatment with Rubraca but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

  • Weakness
  • Weight loss
  • Fever
  • Frequent infections
  • Blood in urine or stool
  • Shortness of breath
  • Feeling very tired
  • Bruising or bleeding more easily

warning Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve. 

warning Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

warning

  • Are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.

warning

  • Are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

warning Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 

warning  While taking Rubraca, avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may burn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

warning The most common side effects of Rubraca include:

  • Nausea 
  • Tiredness or weakness
  • Vomiting
  • Decrease in hemoglobin (anemia)
  • Changes in how food tastes
  • Constipation
  • Decrease in appetite 
  • Diarrhea
  • Low blood cell counts
  • Mouth sores
  • Upper respiratory tract infection
  • Shortness of breath
  • Rash
  • Changes in liver or kidney function blood tests
  • Stomach (abdomen) pain
  • Increased cholesterol levels

warning These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

warning  You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.

INDICATIONS

What is Rubraca?

Rubraca® (rucaparib) tablets are a prescription medicine used for:

  • The maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
  • The treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children. 

SELECT IMPORTANT SAFETY INFORMATION

Read full

warning Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

warning Symptoms of low blood cell counts are common during treatment with Rubraca but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

  • Weakness
  • Weight loss
  • Fever
  • Frequent infections
  • Blood in urine or stool
  • Shortness of breath
  • Feeling very tired
  • Bruising or bleeding more easily

warning Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve. 

warning Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

warning

  • Are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.

warning

  • Are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

warning Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 

warning  While taking Rubraca, avoid spending time in sunlight. Rubraca can make your skin sensitive to the sun (photosensitivity). You may burn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

warning The most common side effects of Rubraca include:

  • Nausea 
  • Tiredness or weakness
  • Vomiting
  • Decrease in hemoglobin (anemia)
  • Changes in how food tastes
  • Constipation
  • Decrease in appetite 
  • Diarrhea
  • Low blood cell counts
  • Mouth sores
  • Upper respiratory tract infection
  • Shortness of breath
  • Rash
  • Changes in liver or kidney function blood tests
  • Stomach (abdomen) pain
  • Increased cholesterol levels

warning These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

warning  You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.